Once-weekly ALTUVIIIO® approved in Japan as a new class of factor VIII therapy for hemophilia A Post author: Post published:September 25, 2023 Post category:uncategorized The Japanese Ministry of Health, Labor, and Welfare (MHLW) has granted marketing authorization for ALTUVIIIO. You Might Also Like NUS study reveals key mechanisms behind drug resistance in relapsed acute myeloid leukemia March 19, 2024 Pomegranate peel extract restores skin balance, fights infections August 5, 2024 Are urban green spaces beneficial to air quality? February 1, 2024
NUS study reveals key mechanisms behind drug resistance in relapsed acute myeloid leukemia March 19, 2024